ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 25,826,838 shares, a growth of 35.0% from the February 26th total of 19,137,458 shares. Based on an average trading volume of 3,625,752 shares, the days-to-cover ratio is currently 7.1 days. Currently, 11.3% of the shares of the company are short sold.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms acquired 7,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This represents a 2.12% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ADMA. Salomon & Ludwin LLC bought a new position in shares of ADMA Biologics during the 3rd quarter valued at approximately $25,000. Rothschild Investment LLC raised its stake in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,495 shares during the period. Summit Securities Group LLC purchased a new position in ADMA Biologics during the fourth quarter valued at approximately $29,000. Clearstead Advisors LLC lifted its holdings in ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics in the third quarter worth approximately $34,000. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

ADMA has been the topic of a number of research reports. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $32.00.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

ADMA Biologics Trading Up 11.6%

Shares of ADMA Biologics stock opened at $9.25 on Friday. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $25.67. The company’s fifty day simple moving average is $15.60 and its 200-day simple moving average is $16.42. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock has a market capitalization of $2.20 billion, a PE ratio of 15.42 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same period in the prior year, the business posted $0.46 EPS. ADMA Biologics’s revenue was up 18.4% on a year-over-year basis. As a group, equities analysts anticipate that ADMA Biologics will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.